Document Type: Research(Original) Article

Authors

Abstract

Bacteriophages (phages) are natural particles to deal with bacteria. The resistance of bacteria to various antibiotics has accelerated in recent years and phages can be used for each particular strain. The best way to deal with superficial infections is topical application of the drug. One of the best way is the use of water-based gels such as hydroxy propyl methyl cellulose (HPMC). In addition to sustain drug release properties of the gel base, HPMC itself has healing properties. The final composition of the gel should has property lasting right time on the woundwhile release a number of the appropriate phages per unit of time. After Isolation and purification of phage, it has been trapped into HPMC gel. Gels with different concentrationsused to create plaques and show the release rate of the phage gel. Finally, it was shown that the 2% HPMC has most appropriate pharmaceutical features In terms of the release and durability on the site of infection.

  1. Haq IU, Chaudhry WN, Akhtar MN, Andleeb S, Qadri I. Bacteriophages and their implications on future biotechnology: a review. Virology journal. 2012;9(1):1.
  2. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future microbiology. 2013;8(6):769-83.
  3. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage. 2011;1(2):111-4.
  4. Rai M, Deshmukh S, Ingle A, Gade A. Silver nanoparticles: the powerful nanoweapon against multidrug‐resistant bacteria. Journal of applied microbiology. 2012;112(5):841-52.
  5. Golkar Z, Bagasra O, Jamil N. Experimental phage therapy on multiple drug resistant Pseudomonas aeruginosa infection in mice. Journal of Antivirals & Antiretrovirals. 2013;2013.
  6. Carlet J, Pulcini C, Piddock L. Antibiotic resistance: a geopolitical issue. Clinical Microbiology and Infection. 2014;20(10):949-53.
  7. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clinical microbiology reviews. 2006;19(2):403-34.
  8. Rose T, Verbeken G, De Vos D, Merabishvili M, Vaneechoutte M, Lavigne R, et al. Experimental phage therapy of burn wound infection: difficult first steps. International journal of burns and trauma. 2014;4(2):66-73.
  9. Thiel K. Old dogma, new tricks--21st Century phage therapy. Nature biotechnology. 2004;22(1):31-6.
  10. Joshi SC. Sol-Gel behavior of hydroxypropyl methylcellulose (hpmc) in ionic media including drug release. Materials. 2011;4(10):1861-905.
  11. Majumdar M. Evaluation of Tectona grandis leaves for wound healing activity: Rajiv Gandhi University of Health Sciences; 2005.
  12. Kelleher PJ. Methods and compositions for the modulation of cell proliferation and wound healing. Google Patents; 2000.
  13. Kropinski AM, Mazzocco A, Waddell TE, Lingohr E, Johnson RP. Enumeration of bacteriophages by double agar overlay plaque assay. Bacteriophages: Methods and Protocols, Volume 1: Isolation, Characterization, and Interactions. 2009:69-76.
  14. Alavidze Z, Aminov R, Betts A, Bardiau M, Bretaudeau L, Caplin J, et al. Silk route to the acceptance and re-implementation of bacteriophage therapy. Biotechnology Journal. 2016;11:1-6.
  15. Estrella LA, Quinones J, Henry M, Hannah RM, Pope RK, Hamilton T, et al. Characterization of novel Staphylococcus aureus lytic phage and defining their combinatorial virulence using the OmniLog® system. Bacteriophage. 2016;6(3):e1219440.
  16. Houston DM, Robins B, Bugert JJ, Denyer SP, Heard CM. In vitro permeation and biological activity of punicalagin and zinc (II) across skin and mucous membranes prone to Herpes simplex virus infection. European Journal of Pharmaceutical Sciences. 2017;96:99-106.
  17. Burrowes B, Harper DR, Anderson J, McConville M, Enright MC. Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert review of anti-infective therapy. 2011;9(9):775-85.
  18. Kumari S, Harjai K, Chhibber S. Topical treatment of Klebsiella pneumoniae B5055 induced burn wound infection in mice using natural products. The Journal of Infection in Developing Countries. 2010;4(06):367-77.
  19. Sulakvelidze A. Phage therapy: an attractive option for dealing with antibiotic-resistant bacterial infections. Drug discovery today. 2005;10(12):807-9.